澳门黄金城(线上VIP认证)官网-正版App Store


COLOWELL Noninvasive ColorectalCancer Screening Test

SFRP2+SDC2

COLOWELL uses a patented double-S-target bowel cancer testto predict colorectal cancer risk by combining todetect themethylation levels of the SFRP2 and SDC2 genes in shed cells ina stool sample based on a large-sample data analysis model.

  • 92.2%Clinical Sensitivity
  • 91.9%Clinical Specificity
  • 62.9%High-Grade Intraepithelia[ Neoplasia (HIN)

Global Colorectal Cancer 1.93 million new cases Ranked No. 3

Colorectal cancer is not scary
early detection is key

The slow onset of colorectal cancer, from precancer-ous polyps to cancer, takes 10-15 years. This biological feature makes colorectal cancer suitable for ear-lydetection. Colorectal cancer can be effectively pre-vented by detecting and removing precancerous le-sions such as adenomas.

One-stop localization solution

The COLOWELLone-stop localization solution covers fecal sampling devicenucleic acid extraction kit, nucleic acid purification kit and human SFRP2 andSDC2gene combined methylation detection kit. The whole-process profession -alquality control, digitalization and traceability can assist the clinic to achieveamore convenient and accurate diagnosis of colorectal cancer

Six Advantages of COLOWELLO

Suitable Population

Certificate

Patented invention
ZL201810884870.8
Medical Device Registration Certificate
(in Vitro Diagnostic reagents)
Nationalinstrument registration
20223400637
Eu CE certification
NL-CA002-2022-67703
XML 地图